Safety and efficacy of loratadine (Sch-29851): a new non-sedating antihistamine in seasonal allergic rhinitis. 1987

R J Dockhorn, and A Bergner, and J T Connell, and C J Falliers, and S V Grabiec, and J M Weiler, and M K Shellenberger

Loratadine, a new antihistamine in the non-sedating class, was evaluated for efficacy and safety in treatment of allergic rhinitis in a multicentered study. Loratadine was found to be both safe and efficacious. When administered to patients with seasonal allergic rhinitis, a single daily oral dose of 10 mg is comparable in efficacy to clemastine, 1 mg, given twice daily. The incidence of sedation with loratadine is comparable to placebo and significantly lower than with clemastine. The incidence of anticholinergic side effects with loratadine is low and in this study was comparable to placebo and clemastine.

UI MeSH Term Description Entries
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002214 Capsules Hard or soft soluble containers used for the oral administration of medicine. Capsule,Microcapsule,Microcapsules
D002974 Clemastine A histamine H1 antagonist used as the hydrogen fumarate in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. Meclastine,Mecloprodin,2-(2-(1-(4-Chlorophenyl)-1-phenylethoxy)ethyl)-1-methylpyrrolidine,Clemastine Fumarate,HS-592,Tavegyl,Tavist,HS 592,HS592
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003533 Cyproheptadine A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc. Antergan,Dihexazin,Periactin,Peritol,Viternum
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D006255 Rhinitis, Allergic, Seasonal Allergic rhinitis that occurs at the same time every year. It is characterized by acute CONJUNCTIVITIS with lacrimation and ITCHING, and regarded as an allergic condition triggered by specific ALLERGENS. Hay Fever,Pollen Allergy,Pollinosis,Seasonal Allergic Rhinitis,Hayfever,Allergic Rhinitides, Seasonal,Allergic Rhinitis, Seasonal,Allergies, Pollen,Allergy, Pollen,Fever, Hay,Pollen Allergies,Pollinoses,Rhinitides, Seasonal Allergic,Rhinitis, Seasonal Allergic,Seasonal Allergic Rhinitides
D006633 Histamine Antagonists Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. Classical antihistaminics block the histamine H1 receptors only. Antihistamine,Antihistamines,Histamine Antagonist,Antagonist, Histamine,Antagonists, Histamine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R J Dockhorn, and A Bergner, and J T Connell, and C J Falliers, and S V Grabiec, and J M Weiler, and M K Shellenberger
June 1984, Agents and actions,
R J Dockhorn, and A Bergner, and J T Connell, and C J Falliers, and S V Grabiec, and J M Weiler, and M K Shellenberger
December 1994, Agents and actions,
R J Dockhorn, and A Bergner, and J T Connell, and C J Falliers, and S V Grabiec, and J M Weiler, and M K Shellenberger
June 1989, The Journal of allergy and clinical immunology,
R J Dockhorn, and A Bergner, and J T Connell, and C J Falliers, and S V Grabiec, and J M Weiler, and M K Shellenberger
August 1986, Agents and actions,
R J Dockhorn, and A Bergner, and J T Connell, and C J Falliers, and S V Grabiec, and J M Weiler, and M K Shellenberger
January 1987, Allergy,
R J Dockhorn, and A Bergner, and J T Connell, and C J Falliers, and S V Grabiec, and J M Weiler, and M K Shellenberger
October 1989, Annals of allergy,
R J Dockhorn, and A Bergner, and J T Connell, and C J Falliers, and S V Grabiec, and J M Weiler, and M K Shellenberger
February 1990, Allergy,
R J Dockhorn, and A Bergner, and J T Connell, and C J Falliers, and S V Grabiec, and J M Weiler, and M K Shellenberger
January 1986, European journal of clinical pharmacology,
R J Dockhorn, and A Bergner, and J T Connell, and C J Falliers, and S V Grabiec, and J M Weiler, and M K Shellenberger
April 1988, Annals of allergy,
R J Dockhorn, and A Bergner, and J T Connell, and C J Falliers, and S V Grabiec, and J M Weiler, and M K Shellenberger
December 1991, Clinical otolaryngology and allied sciences,
Copied contents to your clipboard!